Detalles de la búsqueda
1.
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
Invest New Drugs;
38(2): 457-467, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31065954
2.
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol;
17(6): 822-835, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27132212
3.
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
Oncologist;
21(3): 292-300, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26888693
4.
The European initiative for quality management in lung cancer care.
Eur Respir J;
43(5): 1254-77, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24659546
5.
Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Future Oncol;
10(12): 1925-39, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24856155
6.
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
JTO Clin Res Rep;
5(3): 100638, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38455595
7.
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
Lung Cancer;
166: 84-93, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35245844
8.
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
J Clin Oncol;
40(12): 1301-1311, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35108059
9.
Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data.
Acta Clin Belg;
76(3): 224-231, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31935159
10.
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
J Thorac Oncol;
16(5): 860-867, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33476803
11.
Lung cancer: progress in diagnosis, staging and therapy.
Respirology;
15(1): 44-50, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20199634
12.
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Pathol Oncol Res;
26(2): 1221-1228, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228073
13.
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Clin Cancer Res;
26(7): 1725-1735, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31732522
14.
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
J Thorac Oncol;
15(3): 392-403, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634667
15.
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol;
15(2): 288-293, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31622733
16.
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(31): 3101-3109, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30156984
17.
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
Clin Lung Cancer;
19(4): 331-339, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773328
18.
Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
Cancer Treat Rev;
32 Suppl 2: S11-5, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16725268
19.
Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Am Soc Clin Oncol Educ Book;
35: e450-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27249753
20.
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
PLoS One;
11(3): e0147599, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27032107